As a life science company executive, you must assume that each project will deliver a commercial product and the patenting decisions you make today will have to protect a sizeable R&D investment and global sales for up to 25 years in the future. Your global patent strategy can make or break your company. Any patent strategy that does not take into account—at the patent filing and prosecution stages—the differences between U.S. and European patent law is unlikely to be effective.
The speakers for this Finnegan webinar have many years of experience strategically building, managing, and enforcing multinational patent portfolios. In light of recent U.S. patent decisions and U.S. patent law reform, they will discuss the following four critical questions you need to ask now to be sure U.S. patents are strong, valid, and enforceable:
• What patent applications should be filed and where before 16 March 2013?
• What does the patent really protect and is it enough?
• Does the patent application meet both the U.S. enablement and written description requirements?
• Have the patent attorney and the inventor(s) told the U.S. patent office everything they should?
This webinar is the first in Finnegan’s 2012 series, “What Every Life Science Company Executive Needs to Know About Patents.” We hope you are able to attend.
Moderator:
Marcus Kretzschmar, Ph.D.
Speakers:
Marian T. Flattery
Michael J. Flibbert
Date:
Thursday, June 28, 2012
Time:
14:00 CEST
8:00 EDT
